Andre Kleensang

Andre Kleensang

Auto-generated profile, based on publicly available information

Andre Kleensang

Department of Environmental Health and Engineering, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Aleksander SkardalAleksander Skardal
Aleksander Skardal
SMSean V. Murphy
Sean V. Murphy
MDMahesh Devarasetty
Mahesh Devarasetty
IMIvy Mead
Ivy Mead
HKHyun-Wook Kang
Hyun-Wook Kang
Anthony AtalaAnthony Atala
Anthony Atala
Many drugs have progressed through preclinical and clinical trials and have been available – for years in some cases – before being recalled by the FDA for unanticipated toxicity in humans. One reason for such poor translation from drug candidate to successful use is a lack of model systems that accurately recapitulate normal tissue function of human organs and their response to drug compounds. Moreover, tissues in the body do not exist in isolation, but reside in a highly integrated and dynamically interactive environment, in which actions in one tissue can affect other downstream tissues. Few engineered model systems, including the growing variety of organoid and organ-on-a-chip platforms, have so far reflected the interactive nature of the human body. To address this challenge, we have developed an assortment of bioengineered tissue organoids and tissue constructs that are integrated in a closed circulatory perfusion system, facilitating inter-organ responses. We describe a three-tissue organ-on-a-chip system, comprised of liver, heart, and lung, and highlight examples of inter-organ responses to drug administration. We observe drug responses that depend on inter-tissue interaction, illustrating the value of multiple tissue integration for in vitro study of both the efficacy of and side effects associated with candidate drugs.

1 August 2014 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Open access
FBFrançois Busquet
François Busquet
RSRuben Strecker
Ruben Strecker
JRJane M. Rawlings
Jane M. Rawlings
SBScott E. Belanger
Scott E. Belanger
TBThomas Braunbeck
Thomas Braunbeck
MHMarlies Halder
Marlies Halder
The OECD validation study of the zebrafish embryo acute toxicity test (ZFET) for acute aquatic toxicity testing evaluated the ZFET reproducibility by testing 20 chemicals at 5 different concentrations in 3 independent runs in at least 3 laboratories. Stock solutions and test concentrations were analytically confirmed for 11 chemicals. Newly fertilised zebrafish eggs (20/concentration and control) were exposed for 96h to chemicals. Four apical endpoints were recorded daily as indicators of acute lethality: coagulation of the embryo, lack of somite formation, non-detachment of the tail bud from the yolk sac and lack of heartbeat. Results (LC50 values for 48/96h exposure) show that the ZFET is a robust method with a good intra- and inter-laboratory reproducibility (CV30%) for some very toxic or volatile chemicals, and chemicals tested close to their limit of solubility. The ZFET is now available as OECD Test Guideline 236. Considering the high predictive capacity of the ZFET demonstrated by Belanger et al. (2013) in their retrospective analysis of acute fish toxicity and fish embryo acute toxicity data, the ZFET is ready to be considered for acute fish toxicity for regulatory purposes.

30 May 2013 in Journal of Applied Toxicology
Verified
Journal Article
Closed access
PDF file
MBMounir Bouhifd
Mounir Bouhifd
Thomas HartungThomas Hartung
Thomas Hartung
HHHelena T. Hogberg
Helena T. Hogberg
AKAndre Kleensang
Andre Kleensang
LZLiang Zhao
Liang Zhao


26 July 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AKAndre Kleensang
Andre Kleensang
MVMarguerite M. Vantangoli
Marguerite M. Vantangoli
SOShelly Odwin-DaCosta
Shelly Odwin-DaCosta
MAMelvin E. Andersen
Melvin E. Andersen
KBKim Boekelheide
Kim Boekelheide
Thomas HartungThomas Hartung
Thomas Hartung
Common recommendations for cell line authentication, annotation and quality control fall short addressing genetic heterogeneity. Within the Human Toxome Project, we demonstrate that there can be marked cellular and phenotypic heterogeneity in a single batch of the human breast adenocarcinoma cell line MCF-7 obtained directly from a cell bank that are invisible with the usual cell authentication by short tandem repeat (STR) markers. STR profiling just fulfills the purpose of authentication testing, which is to detect significant cross-contamination and cell line misidentification. Heterogeneity needs to be examined using additional methods. This heterogeneity can have serious consequences for reproducibility of experiments as shown by morphology, estrogenic growth dose-response, whole genome gene expression and untargeted mass-spectroscopy metabolomics for MCF-7 cells. Using Comparative Genomic Hybridization (CGH), differences were traced back to genetic heterogeneity already in the cells from the original frozen vials from the same ATCC lot, however, STR markers did not differ from ATCC reference for any sample. These findings underscore the need for additional quality assurance in Good Cell Culture Practice and cell characterization, especially using other methods such as CGH to reveal possible genomic heterogeneity and genetic drifts within cell lines.

1 April 2019 in Cell Reports
Verified
Journal Article
Open access
TNTu Nguyen
Tu Nguyen
BKBrian James Kirsch
Brian James Kirsch
RARyoichi Asaka
Ryoichi Asaka
KNKarim Nabi
Karim Nabi
AQAddison Quinones
Addison Quinones
ALAnne Le
Anne Le
N-acetyl-aspartyl-glutamate (NAAG) is a peptide-based neurotransmitter that has been extensively studied in many neurological diseases. In this study, we show a specific role of NAAG in cancer. We found that NAAG is more abundant in higher grade cancers and is a source of glutamate in cancers expressing glutamate carboxypeptidase II (GCPII), the enzyme that hydrolyzes NAAG to glutamate and N-acetyl-aspartate (NAA). Knocking down GCPII expression through genetic alteration or pharmacological inhibition of GCPII results in a reduction of both glutamate concentrations and cancer growth. Moreover, targeting GCPII in combination with glutaminase inhibition accentuates these effects. These findings suggest that NAAG serves as an important reservoir to provide glutamate to cancer cells through GCPII when glutamate production from other sources is limited. Thus, GCPII is a viable target for cancer therapy, either alone or in combination with glutaminase inhibition.